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Clinical / Scientific note
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Pisa syndrome (PS) is a rare condition of acute or tar-
dive dystonia characterized by a body involuntary sus-
tained lateral flexion with the head to one side, creat-
ing a “leaning tower” posture. The essential symptoms for 
the diagnosis of PS are the presence of persistent dysto-
nia of the trunk, and lateral flexion with mildly backward 
axial rotation of the trunk, the absence of other dyston-
ic regions of the body, a history of medication preceding 
or concurrent with the onset of dystonia, the absence 
of known reasons for secondary dystonia, and a negative 
family history for dystonia1. The referential items support-
ing the diagnosis of the syndrome are worsening of the 
posture abnormality in walking, indifference to posture 
abnormality without agony (anosognosia), and improve-
ment in the abnormality of the posture by withdrawal of 
the causal agents1. Different from other side effects relat-
ed to antipsychotic treatment2, there are putative risk fac-
tors described for PS, including previous prolonged treat-
ment with typical antipsychotics, combined pharmaco-
logical treatment, female gender, old age, presence of an 
organic brain disorder3. Most of PS cases have been de-
scribed as adverse effects of prolonged exposure to con-
ventional antipsychotics, however more recently, other 
drugs, including atypical antipsychotics, have been impli-
cated in the pathophysiology of PS4.
We describe the case of a patient with no classical risk 
factors for PS, who developed the disorder induced by 
rapid increase and high dosage of risperidone.
CaSe
An 18-year-old man was admitted to our inpatient unit be-
cause of a severe psychotic exacerbation. Since the diagnosis of 
DSM-IV hebephrenic schizophrenia, two years ago, he had been 
treated with risperidone, a maximum of 4 mg/day, presenting a 
good clinical control. However two months before the admis-
sion, the patient discontinued his medication and began to pres-
ent thought and behavioral disorganization, delusions, auditive 
hallucinations, agitation, insomnia.
In the beginning of the admission, he was administered ris-
peridone 4 mg/day and diazepam 30 mg/day for one month. As 
the clinical features were not improving with such medication, 
the dosage of risperidone was increased until 6 mg/day and di-
azepam was switched to clonazepam 6 mg/day with the aim 
to control the episodes of agitation and insomnia. After three 
weeks with such medication, risperidone was increased to 12 mg 
/day because of the inadequate control of the psychotic symp-
toms. One week after risperidone augmentation, an acute dys-
tonic reaction (tonic flexion of trunk and head toward the left 
along with a slight backward axial rotation) was observed (Fig-
ure). Risperidone was immediately discontinued and an adjunc-
tive treatment with biperiden, an anticholinergic drug, was ini-
tiated. Biperiden was introduced in a dosage of 6 mg/day by 
oral administration. In addition, in the period of three days that 
followed the beginning of PS the patient has received 20 mg of 
biperiden by intramuscular administration. PS completely dis-
appeared within 3 days after risperidone discontinuation and 
complementary anticholinergic therapy. After that, risperidone 
Figure. Patient presenting tonic flexion of trunk and head toward the 
left along with a slight backward axial rotation.
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was switched to olanzapine, until a dosage of 10 mg/day, with a 
good antipsychotic response.
On admission, the physical examination revealed non-fo-
cal neurological deficits. No evidence of other extrapyramidal 
symptoms was found. The patient had no personal history of 
drug abuse, no history of head trauma or other neurological 
problems, and no family history of dystonia or other movement 
disorders. Secondary dystonias resulting from metabolic disor-
der, organic disorder, or infection were ruled out.
diSCuSSion
A dysfunction of cerebral dopaminergic pathways, 
which are strategic in the regulation of axial muscle tone, 
has been related as a possible central factor in PS patho-
physiology5. Risperidone is a selective monoaminergic an-
tagonist with a high affinity for dopaminergic D2 recep-
tors. Blockade of D2 receptors by classical antipsychotics 
ameliorate the positive symptoms of schizophrenia. How-
ever, this blockade is considered responsible for the oc-
currence of extrapyramidal symptoms. At therapeutic 
dosages, risperidone’s combined serotonin and dopamine 
antagonism is supposed to be responsible for its effec-
tiveness on positive and possibly negative symptoms of 
schizophrenia and its lack of extrapyramidal side effects 
at dosages lower than 6 mg/day. The reported incidence 
of acute dystonia with risperidone is greater than pla-
cebo at high dosages (16 mg/day), however no greater 
than placebo in dosages lower than 6 mg/day6. In clinical 
populations, risperidone has been associated with dos-
age-dependent induction of extrapyramidal adverse ef-
fects occurring in the upper dosage range (>6 mg/day)6,7. 
Therefore, high dosages of risperidone may be associated 
with extrapyramidal side effects, such as dystonia7. In the 
present report, such phenomenon may be happened, as 
the patient has received a high dosage of risperidone (12 
mg/day) before the occurrence of acute dystonia.
Rapid increase of a dopaminergic antipsychotic may 
also be involved in the onset of dystonia7. A previous case 
of dystonia appearance related to rapid increase of ris-
peridone dosage was reported, however with no PS man-
ifestation8. Moreover other case reports of PS-induced 
risperidone have also been described9, nevertheless in the 
present case the patient had no history of putative risk 
factors described for PS.
Once the PS begins, the treatment remains empirical, 
which reflects the poor understanding of its underlying 
pathophysiology10. The first-line treatment for PS has been 
the reduction in dosage or discontinuation of antipsychot-
ics, while the second-line treatment has been the intro-
duction of an anticholinergic medication, as PS is a side 
effect caused by the central dopaminergic blockade9.
In the follow-up of patients who presented PS with ris-
peridone, the substitution to other atypical antipsychot-
ics that does not present high affinity for dopaminergic 
D2 receptors, as olanzapine, may provide an interesting 
alternative for their treatment, as occurred in the pres-
ent case report9.
In summary, clinicians should be aware of rapid upward 
titration and high dosage of risperidone because these 
conditions may precipitate PS even in patients without 
risk factors for the development of such adverse effect. 
Once the patient presents PS, the treatment may include 
the reduction in dosage or discontinuation of the antipsy-
chotic drug, associated to the introduction of an anticho-
linergic medication, and in the follow-up drugs with low 
affinity for dopaminergic D2 receptors must be used.
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